--Ecuadorian Rainforest LLC (Belleville, NJ) relaunched its Web site on August 1. The Web site, located at www.intotherainforest.com, includes a monthly video blog, interactive polls, and real-time news.
--Improve USA Inc. (Desoto, TX) completed an expansion of its Proeza processing facility in Jaumave, Mexico. The expansion, Improve’s third in four years, creates a 67,000-sq-ft facility dedicated to processing the company’s DaltonMax700 dehyrated Aloe vera powder. In addition to providing the capacity to process 80 tons of leaves per day, the facility also houses R&D and microbiology labs, along with 10 stainless-steel low-vacuum drying units.
--Farbest Brands (Montvale, NJ) and BioGin Biochemicals (Chengdu, China) formed an alliance to leverage their national sales and distribution networks to market omega-3s in North America. The BioGin line of omega-3 fatty acids contain a broad range of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and alpha linolenic acid (ALA) from fish and flax seed oils, while AlaLife ingredients contain concentrated amounts of omega-3s.
--Fenchem (Chino, CA) achieved a 10% sales increase in the United States market from January to June, compared with the same period in 2007. To accommodate increasing demand, Fenchem is expanding its China factory’s production capacities, focusing on the production of Tocovet vitamin E and Cholevel phytosterols.
--Gencor Pacific Inc. (Anaheim, CA) received U.S. patent 7,390,516 for its Slimaluma Caralluma fimbriata extract. The patent covers “caralluma extract products and processes for making the same.”
--Sensus (Roosendall, The Netherlands) launched a new Web site that describes the latest information about inulin and chicory, as well as their use in various applications. The Web site is located at www.sensus.nl .
--Lonza (Allendale, NJ) appointed Seltzer Ingredients (Carlsbad, CA) and Pharmachem Laboratories (Kearny, NJ) as distributors for its Carnipure brand of L-carnitine. The appointments will enable Lonza to reduce shipping time and provide regional technical support.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.